Hantschel, Oliver <br/><br/>
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.  [electronic resource] 

 -  Proceedings of the National Academy of Sciences of the United States of America  Aug 2007 
 - 13283-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0027-8424 
<br/><br/><label>Standard No.: </label>10.1073/pnas.0702654104  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Basophils--drug effects<br/>Dasatinib<br/>Enzyme-Linked Immunosorbent Assay<br/>Fusion Proteins, bcr-abl<br/>Histamine Release--drug effects<br/>Humans<br/>K562 Cells<br/>Mice<br/>Mice, Inbred C57BL<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrimidines--pharmacology<br/>Thiazoles--pharmacology<br/>U937 Cells